Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New chief medical officer at Clavis Pharma

This article was originally published in Scrip

Executive Summary

Clavis Pharma (Norway) has appointed Dr Athos Gianella-Borradori chief medical officer. Dr Gianella-Borradori is an onco-haematologist and drug developer, having spent the past 20 years in industry, focused on translational research and on the clinical development of anticancer agents. During this career, he has held managerial and senior clinical R&D roles at Novartis, Crucell, Bavarian Nordic, Cyclacel and, for the last five years, at Serono (later at Merck Serono). Dr Gianella-Borradori's primary role at Clavis will be to drive the clinical development of, elacytarabine, which is in Phase III for patients with acute myeloid leukaemia, and of CP-4126 in partnership with Clovis Oncology, which is in Phase II development for patients with pancreatic cancer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel